Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03761160 Completed - Prostate Cancer Clinical Trials

Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

Start date: July 16, 2019
Phase: N/A
Study type: Interventional

This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.

NCT ID: NCT03749993 Completed - Prostate Cancer Clinical Trials

Evaluation of a MRI-based Prostate Cancer Screening Program

VISIONING
Start date: January 10, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effort and resources (incl. costs) required to detect 20 clinically relevant prostate cancer (PCA) in a screening program based on bpMRI of the prostate.

NCT ID: NCT03744494 Completed - Prostate Cancer Clinical Trials

Cosmetic Appeal, HRQoL and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer

TEPSO
Start date: March 2, 2016
Phase: N/A
Study type: Interventional

The therapeutic efficacy of three types of orchidectomy was ascertained as well as the QoL and scrotal cosmetic satisfaction of patients in the three surgical arms. Two of these surgeries produced a pseudotesticle (BSCO, BESO) while one (BSO) did not.

NCT ID: NCT03739684 Completed - Prostate Cancer Clinical Trials

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

CONDOR
Start date: November 27, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

NCT ID: NCT03735680 Completed - Breast Cancer Clinical Trials

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

Start date: August 9, 2019
Phase: Phase 2
Study type: Interventional

This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine surgery.

NCT ID: NCT03730324 Completed - Prostate Cancer Clinical Trials

Predicting Prostate Biopsy Results With Biomarkers and mpMRI.

ProBioM
Start date: November 5, 2018
Phase: N/A
Study type: Interventional

Current standard prostate biopsy techniques, used to definitively diagnose prostate cancer (PC), utilises an ultrasound guided biopsy approach, that offers unsatisfactory specificity and sensitivity for clinical significant PC. This often leads to harmful unnecessary biopsies. To improve the overall detection of clinical significant PC, multiparametric magnetic resonance imaging (mpMRI) has emerged as a new technique that might be useful in selecting the appropriate patient for biopsy. Nevertheless, mpMRI fail to detect cancer in some circumstances and the exact role of mpMRI is undetermined. Currently, the majority of PC is diagnosed either incidentally or by unsystematic screening with prostate specific antigen (PSA). PSA suffers from being an organ specific, but cancer unspecific serum biomarker. PSA testing may neither rule out or confirm the presence of prostate cancer. Newer biomarkers have shown promise in curbing some of this sensitivity and specificity gap, but still needs refinement. In the present study, the investigators will use mpMRI and a new set of urine and plasma biomarkers in combination, prior to performing standard biopsies in order to develop a prediction model for the biopsy outcome. If proven successful the model would offer excellent risk stratification and possibly mitigating the need for biopsies.

NCT ID: NCT03726320 Completed - Prostate Cancer Clinical Trials

Trial of Community Health Worker-led Decision Coaching

Start date: October 15, 2019
Phase: N/A
Study type: Interventional

Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the U.S. This randomized trial will evaluate the efficacy of a Community Health Worker-led decision coaching program to facilitate Shared Decision Making (SDM) and Prostate Specific Antigen (PSA) screening among Black men with regards to decision quality, the decision making process, patient-provider communication and PSA utilization for Black men in the primary care setting.

NCT ID: NCT03693742 Completed - Prostate Cancer Clinical Trials

MSG Use With 18F-DCFPyL PET/CT Imaging

Start date: November 4, 2019
Phase: N/A
Study type: Interventional

18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells. Unfortunately when this treatment is delivered there is radiotracer uptake in the salivary glands and kidneys, not related to cancer, which causes dry mouth and causes patients to stop treatment. It is proposed that having tomato juice containing monosodium glutamate (MSG) may reduce radiotracer uptake in the salivary glands and kidneys and reduce damage to these tissues.

NCT ID: NCT03692585 Completed - Prostate Cancer Clinical Trials

Ethnographic Study of the Everyday Life of Men With Prostate Cancer, Focusing on Diet, Activities and Digital Behavior

EMIL
Start date: June 2015
Phase:
Study type: Observational

This is an ethnographic study to investigate the competences and preferences in everyday living of men with prostate cancer, using participant observation and semi-structured interviews. The study will work as the need assessment part of the emil project, which aims to design, develop, implement and evaluate a digital service to support a healthy lifestyle among men with prostate cancer.

NCT ID: NCT03692104 Completed - Prostate Cancer Clinical Trials

US-CT Fusion for Post Implant Dosimetry

Start date: November 3, 2017
Phase:
Study type: Observational

Post implant dosimetry is an essential part of quality assurance after permanent seed prostate brachytherapy. CT imaging is the standard of assessment but due to contouring uncertainties, MR-CT fusion is preferred. This is not always available due to financial restrictions. This study explores the possibility of post implant US-CT fusion to improve contouring accuracy and potentially replace the use of MR-CT fusion.